A Canadian Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus

CompletedOBSERVATIONAL
Enrollment

662

Participants

Timeline

Start Date

October 29, 2018

Primary Completion Date

April 25, 2019

Study Completion Date

April 26, 2019

Conditions
Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2
Interventions
DRUG

Insulin degludec

Participants are treated with Tresiba® (insulin degludec) under conditions of routine care.

Trial Locations (32)

T2H 2G4

Novo Nordisk Investigational Site, Calgary

T5T 3J7

Novo Nordisk Investigational Site, Edmonton

V6J 4Y3

Novo Nordisk Investigational Site, Vancouver

B3H 2Y9

Novo Nordisk Investigational Site, Halifax

B2T 1A4

Novo Nordisk Investigational Site, Shubenacadie

B1P 1P3

Novo Nordisk Investigational Site, Sydney

L1Z 0M1

Novo Nordisk Investigational Site, Ajax

L6S 0C6

Novo Nordisk Investigational Site, Brampton

N1R 7L6

Novo Nordisk Investigational Site, Cambridge

L4K 4M2

Novo Nordisk Investigational Site, Concord

M9R 4E1

Novo Nordisk Investigational Site, Etobicoke

N1H 3R3

Novo Nordisk Investigational Site, Guelph

N6A 4V2

Novo Nordisk Investigational Site, London

N6G 2M1

Novo Nordisk Investigational Site, London

L3P 7P2

Novo Nordisk Investigational Site, Markham

L3S 0A2

Novo Nordisk Investigational Site, Markham

K2J 0V2

Novo Nordisk Investigational Site, Nepean

L6M 1M1

Novo Nordisk Investigational Site, Oakville

L3V 2Z6

Novo Nordisk Investigational Site, Orillia

M1E 5E9

Novo Nordisk Investigational Site, Scarborough Village

K7A 4W8

Novo Nordisk Investigational Site, Smiths Falls

N8N 4M7

Novo Nordisk Investigational Site, Tecumseh

M4G 3E8

Novo Nordisk Investigational Site, Toronto

M6G 1M2

Novo Nordisk Investigational Site, Toronto

J8Y 0A7

Novo Nordisk Investigational Site, Gatineau

H7T 2P5

Novo Nordisk Investigational Site, Laval

H2K 1H2

Novo Nordisk Investigational Site, Montreal

H4A 2C6

Novo Nordisk Investigational Site, Montreal

H4A 3T2

Novo Nordisk Investigational Site, Montreal

H4T 1Z9

Novo Nordisk Investigational Site, Montreal

H8Z 1W5

Novo Nordisk Investigational Site, Pierrefonds

J6X 4P7

Novo Nordisk Investigational Site, Terrebonne

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT03674866 - A Canadian Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter